STRATA Skin Sciences (SSKN) announced that it has entered into definitive securities purchase agreements with certain institutional investors for the purchase and sale of 1,097,547 shares of the Company’s common stock at a per share purchase price of $2.204, in a registered direct offering, priced at-market under Nasdaq rules. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent for the offering. The closing of the registered direct offering is expected to occur on or about September 4, 2025, subject to the satisfaction of customary closing conditions . The gross proceeds to The Company from the registered direct offering, before deducting the placement agent fees and other offering expenses payable by the Company, are expected to be approximately $2.42 million. The Company intends to use the net proceeds from the offerings for working capital and for general corporate purposes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SSKN:
- STRATA affirms its IP portfolio exclusivity in XTRAC, JAK inhibitor combo
- Strata Skin Sciences’ Earnings Call: Mixed Sentiments and Strategic Moves
- Strata Skin Sciences Faces Nasdaq Compliance Notice
- Strata Skin Sciences Unveils Strategic Initiatives
- STRATA Skin Sciences Reports Q2 2025 Financial Results